BioRestorative Therapies (FRA:9OF) 3-Year Revenue Growth Rate : -31.30% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies 3-Year Revenue Growth Rate?

BioRestorative Therapies's Revenue per Share for the three months ended in Dec. 2023 was €0.00.

During the past 12 months, BioRestorative Therapies's average Revenue per Share Growth Rate was 6.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was -31.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was -77.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was -64.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of BioRestorative Therapies was 80.70% per year. The lowest was -89.80% per year. And the median was -61.10% per year.

Competitive Comparison of BioRestorative Therapies's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, BioRestorative Therapies's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioRestorative Therapies's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's 3-Year Revenue Growth Rate falls into.

BioRestorative Therapies 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

BioRestorative Therapies (FRA:9OF) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

BioRestorative Therapies 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

BioRestorative Therapies (FRA:9OF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (FRA:9OF) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

BRTX:USA

Address

40 Marcus Drive, Suite One, Melville, NY, USA, 11747

Website

https://www.biorestorative.com

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

BioRestorative Therapies (FRA:9OF) Headlines

No Headlines